JP2018538335A5 - - Google Patents

Download PDF

Info

Publication number
JP2018538335A5
JP2018538335A5 JP2018532639A JP2018532639A JP2018538335A5 JP 2018538335 A5 JP2018538335 A5 JP 2018538335A5 JP 2018532639 A JP2018532639 A JP 2018532639A JP 2018532639 A JP2018532639 A JP 2018532639A JP 2018538335 A5 JP2018538335 A5 JP 2018538335A5
Authority
JP
Japan
Prior art keywords
gdf15
therapeutic agent
seq
conjugate
hgdf15
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018532639A
Other languages
English (en)
Japanese (ja)
Other versions
JP6946304B2 (ja
JP2018538335A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/057839 external-priority patent/WO2017109706A1/en
Publication of JP2018538335A publication Critical patent/JP2018538335A/ja
Publication of JP2018538335A5 publication Critical patent/JP2018538335A5/ja
Application granted granted Critical
Publication of JP6946304B2 publication Critical patent/JP6946304B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018532639A 2015-12-22 2016-12-20 増殖分化因子15(gdf−15)を使用して代謝障害を処置するまたは軽快させる方法 Expired - Fee Related JP6946304B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562270967P 2015-12-22 2015-12-22
US62/270,967 2015-12-22
PCT/IB2016/057839 WO2017109706A1 (en) 2015-12-22 2016-12-20 Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)

Publications (3)

Publication Number Publication Date
JP2018538335A JP2018538335A (ja) 2018-12-27
JP2018538335A5 true JP2018538335A5 (cg-RX-API-DMAC10.html) 2020-01-30
JP6946304B2 JP6946304B2 (ja) 2021-10-06

Family

ID=57796765

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018532639A Expired - Fee Related JP6946304B2 (ja) 2015-12-22 2016-12-20 増殖分化因子15(gdf−15)を使用して代謝障害を処置するまたは軽快させる方法

Country Status (5)

Country Link
US (2) US20190000923A1 (cg-RX-API-DMAC10.html)
EP (1) EP3393494A1 (cg-RX-API-DMAC10.html)
JP (1) JP6946304B2 (cg-RX-API-DMAC10.html)
CN (1) CN108367053A (cg-RX-API-DMAC10.html)
WO (1) WO2017109706A1 (cg-RX-API-DMAC10.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5977814B2 (ja) 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子15(gdf−15)を使用して代謝障害を治療または改善する方法
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド 代謝障害を治療するための組成物および方法
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
LT3027642T (lt) 2013-07-31 2020-10-12 Amgen Inc. Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
JP6704358B2 (ja) 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を治療するための組成物および使用方法
US10004596B2 (en) 2014-07-31 2018-06-26 Lensgen, Inc. Accommodating intraocular lens device
CN106687128B (zh) 2014-10-31 2022-05-10 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
JP7296728B2 (ja) * 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
KR102433503B1 (ko) 2016-05-24 2022-08-18 노보 노르디스크 에이/에스 Mic-1 화합물 및 이것의 사용
EP3538124A4 (en) * 2016-11-13 2020-07-22 Imagine Pharma COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES, HYPERTENSION AND HYPERCHOLESTEROLEMIA
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Mic-1化合物及其用途
JP2020533302A (ja) 2017-09-10 2020-11-19 ノヴォ ノルディスク アー/エス 肥満の治療において使用するためのmic−1およびglp−1
TWI724392B (zh) * 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
US12054527B2 (en) * 2018-04-09 2024-08-06 Amgen Inc. Growth differentiation factor 15 fusion proteins
WO2020009740A2 (en) * 2018-04-25 2020-01-09 Washington University Compositions and methods of use thereof for treatment of metabolic diseases and related disorders
EP3833974A2 (en) 2018-08-10 2021-06-16 Novartis AG Gfral extracellular domains and methods of use
MY205905A (en) 2018-10-22 2024-11-20 Janssen Pharmaceutica Nv Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
CN113474363A (zh) * 2018-11-20 2021-10-01 詹森药业有限公司 用于降低体重和/或减少食物摄取量的gdf15类似物和方法
US20220098252A1 (en) 2019-01-25 2022-03-31 Ospedale San Raffaele S.R.L. Inhibitor of dux4 and uses thereof
BR112021021271A2 (pt) * 2019-04-23 2021-12-21 Lg Chemical Ltd Polipeptídeo de fusão compreendendo região fc de imunoglobulina e gdf15
ES3061099T3 (en) 2019-10-04 2026-03-31 Amgen Inc Use of gdf15 for treating cardiometabolic syndrome and other conditions
EP4081241A4 (en) * 2019-12-24 2024-05-01 Juvena Therapeutics, Inc. REGENERATIVE POLYPEPTIDES AND USES THEREOF
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
CN113366024B (zh) * 2020-01-08 2024-11-05 上海翰森生物医药科技有限公司 Fgf21突变体蛋白及其融合蛋白
CN111333505B (zh) * 2020-03-31 2022-07-26 东莞市东阳光生物药研发有限公司 制备长链脂肪二酸单苄酯的方法及其应用
EP4237438A4 (en) 2020-10-27 2024-11-27 Beijing QL Biopharmaceutical Co., Ltd. GDF15 FUSION PROTEINS AND THEIR USE
KR102569644B1 (ko) * 2020-10-30 2023-08-23 가톨릭대학교 산학협력단 Gdf15를 유효성분으로 함유하는 면역질환의 예방 및 치료용 조성물
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
EP4351627A4 (en) * 2021-05-21 2025-06-04 Yuhan Corporation COMPOSITION FOR COMBINATION THERAPY COMPRISING A GROWTH DIFFERENTIATION FACTOR 15 VARIANT AND A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST
AU2022278933A1 (en) * 2021-05-21 2023-12-07 Yuhan Corporation Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
JP2025505198A (ja) 2022-02-10 2025-02-21 ノバルティス アーゲー 肥満の治療のためのglp1受容体の活性化因子としての2-((4-((s)-2-(4-クロロ-2-フルオロフェニル)-2-メチルベンゾ[d][1,3]ジオキソール-4-イル)ピペリジン-1-イル)メチル)-1-(((s)-オキセタン-2-イル)メチル)-1h-イミダゾール誘導体
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
JP2024058473A (ja) * 2022-10-14 2024-04-25 国立大学法人九州大学 筋線維芽細胞のα-平滑筋アクチン及びコラーゲンの発現抑制剤、線維症治療用医薬組成物、並びに、in vitroで筋線維芽細胞のα-平滑筋アクチン及びコラーゲンの産生を抑制する方法
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.
CN118995820A (zh) * 2024-10-22 2024-11-22 江苏凯基生物技术股份有限公司 一种生长分化因子-15及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
ATE423788T1 (de) 1995-06-22 2009-03-15 St Vincents Hosp Sydney Neues tgf-beta-ahnliches cytokin
WO1998019523A1 (fr) * 1996-11-01 1998-05-14 Shionogi & Co., Ltd. Souris modele pour maladies affectant l'homme
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
ES2464532T3 (es) 2001-04-19 2014-06-03 The Scripps Research Institute Métodos y composiciones para la producción de pares ortogonales de ARNt-aminoacil-ARNt sintetasa
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
US20030138417A1 (en) 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
AR044399A1 (es) 2003-05-20 2005-09-14 Novartis Ag Compuestos heterociclicos y su uso como activadores de receptores de ppar. composiciones farmaceuticas que los contienen
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
US8431558B2 (en) 2004-11-01 2013-04-30 The Regents Of The University Of California Compositions and methods for modification of biomolecules
TW200738261A (en) 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
CA2722829A1 (en) * 2008-05-06 2009-11-12 F. Hoffmann-La Roche Ag Animal model for diabetes
JP5542832B2 (ja) 2008-10-24 2014-07-09 アイアールエム・リミテッド・ライアビリティ・カンパニー 生合成的に製造したピロリン−カルボキシ−リシンならびにピロリン−カルボキシ−リシンおよびピロリシン基の化学誘導体化を介する部位特異的タンパク質修飾
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2012106615A1 (en) * 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
JP5977814B2 (ja) * 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子15(gdf−15)を使用して代謝障害を治療または改善する方法
CA2848711C (en) * 2011-09-16 2019-08-06 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
KR20140125803A (ko) * 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
JP6254146B2 (ja) * 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド 代謝障害を治療するための組成物および方法
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
CA2899170C (en) * 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
LT3027642T (lt) 2013-07-31 2020-10-12 Amgen Inc. Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
CA2952032C (en) * 2014-06-20 2023-03-14 Aveo Pharmaceuticals, Inc. Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
CN106573955B (zh) 2014-06-23 2021-02-26 诺华股份有限公司 位点特异性蛋白质修饰
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
WO2015197446A1 (en) 2014-06-24 2015-12-30 Novo Nordisk A/S Mic-1 fusion proteins and uses thereof
WO2016102580A1 (en) 2014-12-22 2016-06-30 Novo Nordisk A/S Alpha-1-antitrypsin (a1at) fusion proteins and uses thereof

Similar Documents

Publication Publication Date Title
US12370262B2 (en) Messenger RNA vaccines and uses thereof
JP5185813B2 (ja) 癌免疫治療のための組成物および方法
TWI685347B (zh) 用於在活體中遞送RNAi觸發子至腫瘤細胞之聚結合物
CN103491982B (zh) 具有酶敏感性连接的多核苷酸体内递送偶联物
JP2011530599A5 (cg-RX-API-DMAC10.html)
JP2016535009A5 (cg-RX-API-DMAC10.html)
JP2026510392A (ja) 遺伝子編集においてならびにワクチン及び治療剤として使用するためのコードrna分子を含む脂質ナノ粒子
JP2019533707A (ja) Mrna担持脂質ナノ粒子を調製する改善されたプロセス
WO2007030375A3 (en) Lysosomal acid lipase therapy for nafld and related diseases
US9399016B2 (en) Materials and complexes for the delivery of biologically-active materials to cells
EP4171574A1 (en) Compositions and methods for inducing an immune response against coronavirus
ES2981281T3 (es) Composiciones y métodos para modificar la superficie de las células y métodos de uso
ES2220451T3 (es) Tratamiento de una infeccion intracelular.
US20200397848A1 (en) Method of treating a liver disease comprising administering ostreolysin orfunctionally related variant thereof
WO2025128871A2 (en) Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
AU2019381809B2 (en) Compositions and uses of vasoactive intestinal peptide (VIP) antagonists
US20240390483A1 (en) Mucosal messenger rna vaccine
WO2008075706A1 (ja) 間質性肺炎治療剤
EP4651943A1 (en) Lipidoid compounds and related compositions and uses
CN101119743B (zh) 免疫增强剂
Kang Strategies to Design and Refine Lipid Nanoparticles for Functional mRNA Delivery
HK1188947A (en) In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
HK1188947B (en) In vivo polynucleotide delivery conjugates having enzyme sensitive linkages